Market capitalization | $19.22m |
Enterprise Value | $-4.34m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.06 |
EV/Sales (TTM) EV/Sales | -0.21 |
P/S ratio (TTM) P/S ratio | 0.95 |
P/B ratio (TTM) P/B ratio | negative |
Dividend yield | 0.00% |
Last dividend (FY23) | $5.15 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Sesen Bio, Inc. forecast:
5 Analysts have issued a Sesen Bio, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 20 20 |
91%
91%
|
|
Gross Profit | 16 16 |
82%
82%
|
|
EBITDA | -62 -62 |
14%
14%
|
EBIT (Operating Income) EBIT | -67 -67 |
10%
10%
|
Net Profit | -64 -64 |
13%
13%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Steven Kelly |
Employees | 107 |
Founded | 2016 |
Website | carismatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.